US equities
|
NVDA
$237.07
▲+1.34%
SPCX
$165.71
▲+4.25%
MU
$1,064.46
▼-0.97%
TSLA
$377.91
▲+1.98%
MSFT
$526.28
▲+1.69%
INTC
$116.49
▼-2.38%
SNDK
$1,723.32
▲+0.19%
AMD
$628.95
▼-0.78%
NVDA
$237.07
▲+1.34%
SPCX
$165.71
▲+4.25%
MU
$1,064.46
▼-0.97%
TSLA
$377.91
▲+1.98%
MSFT
$526.28
▲+1.69%
INTC
$116.49
▼-2.38%
SNDK
$1,723.32
▲+0.19%
AMD
$628.95
▼-0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Humacyte, Inc. - Common Stock
(NQ:
HUMA
)
0.5100
-0.0100 (-1.92%)
Delayed Quote
Updated: 10:08 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Humacyte, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday
↗
December 20, 2024
Via
Benzinga
Spotlight on Humacyte: Analyzing the Surge in Options Activity
↗
December 20, 2024
Via
Benzinga
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
↗
December 20, 2024
Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair in trauma cases.
Via
Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
↗
December 20, 2024
Via
Benzinga
US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'
↗
December 20, 2024
U.S. futures declined on Friday, ahead of the 'Triple Witching' hour, which is expected to see $6.6 trillion options expire, for the quarter.
Via
Benzinga
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
December 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
December 19, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. Investors of Upcoming Deadline
December 18, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
December 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA
December 17, 2024
Via
ACCESSWIRE
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA
December 16, 2024
Via
ACCESSWIRE
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class Action - HUMA
December 16, 2024
Via
ACCESSWIRE
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
December 16, 2024
Via
ACCESSWIRE
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Humacyte Inc
December 16, 2024
Via
ACCESSWIRE
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders
December 16, 2024
Via
ACCESSWIRE
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky
December 16, 2024
Via
ACCESSWIRE
Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - HUMA
December 15, 2024
Via
ACCESSWIRE
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for Investors - Contact Levi & Korsinsky
December 15, 2024
Via
ACCESSWIRE
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
December 15, 2024
Via
ACCESSWIRE
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class Action - HUMA
December 15, 2024
Via
ACCESSWIRE
Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc.(HUMA)
December 15, 2024
Via
ACCESSWIRE
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – HUMA
December 14, 2024
Via
ACCESSWIRE
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights – HUMA
December 14, 2024
Via
ACCESSWIRE
The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Humacyte Inc
December 14, 2024
Via
ACCESSWIRE
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HUMA
December 14, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
December 13, 2024
Via
ACCESSWIRE
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
December 13, 2024
Via
ACCESSWIRE
Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact Levi & Korsinsky
December 13, 2024
Via
ACCESSWIRE
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
December 13, 2024
Via
ACCESSWIRE
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA
December 13, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
